Sarah Bernhard, PhD, and Susovan Chowdhury, PhD, co-led a study showing how the delta opioid receptor could be targeted to develop safer, more effective pain treatments.
Study uncovers how delta opioid receptor could be harnessed for safer pain therapeutics








